GtoPdb Ligand ID: 10469

Compound class: Antibody
Comment: COVA322 is a bispecific TNF/IL-17A inhibitor that was designed by Covagen for the treatment of inflammatory diseases including psoriasis, psoriatic arthritis, and rheumatoid arthritis [2]. Structurally COVA322 is a fusion protein containing an antibody that binds to TNF (in this case the light chain of adalimumab) and a Fyn SH3-derived protein (Fynomer) that binds to IL-17A [1]. The fusion protein was produced in transiently transfected Chinese hamster ovary (CHO) cells. COVA322 was able to simultaneously bind TNF and IL-17A.
Clinical development of COVA322 was discontinued due to an unacceptable safety profile that was detected in Phase 1 trial.
Bioactivity Comments
COVA322 binds cynomolgus TNF and IL-17A with affinities of 63 pM and 120 pM respectively [2].
Other ligands which bind to or alter the activity of this ligand
Key to terms and symbols Click column headers to sort
Ligand Sp. Type Action Value Parameter Concentration range (M) Reference
IL-17A {Sp: Human} Hs None Binding 10.4 pKd - 2
pKd 10.4 (Kd 3.6x10-11 M) [2]
Description: Binding affinity determined using BIAcore technology.
tumour necrosis factor shed form {Sp: Human} Hs Antibody Binding 9.9 pKd - 2
pKd 9.9 (Kd 1.29x10-10 M) [2]
Description: Binding affinity determined using BIAcore technology